RASONQUE Wins EU Approval for Treated Pancreatic Cancer
The European Commission has approved Revolution Medicines’ once-daily tablet for adults with metastatic pancreatic cancer who have already received systemic treatment. Access will depend on national pricing and reimbursement decisions, and the authorization does not cover the United Kingdom or Switzerland.

Revolution Medicines announced on November 16, 2026, that the European Commission had approved RASONQUE, an oral medicine for previously treated metastatic pancreatic cancer. The decision offers eligible adults in the European Union another treatment option.
The once-daily tablets are approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The drug can be used alone, whether or not a RAS tumor mutation has been identified.
Metastatic cancer has spread beyond its original site. Pancreatic adenocarcinoma is the most common form of pancreatic cancer.
Access Depends on National Decisions
The authorization covers all European Union member states, as well as Iceland, Norway and Liechtenstein. It does not apply in the United Kingdom or Switzerland, which have separate approval processes.
Revolution Medicines said access will vary by country. National pricing, health technology assessments and reimbursement processes must be completed.
Mark A. Goldsmith, the company’s chief executive and chairman, said it was working with health systems and other stakeholders to support access. He said the company was also engaging with regulators elsewhere.
The European Commission acted after a positive opinion from a European Medicines Agency committee. The review was expedited under the agency’s Cancer Medicines Pathfinder project.
Trial Results and Safety Risks
The approval rests on RASolute 302, a global randomized Phase 3 trial. It compared RASONQUE with a doctor’s choice of chemotherapy in people with previously treated metastatic pancreatic adenocarcinoma.
Participants received either 300 mg of RASONQUE once daily or one of four chemotherapy regimens. The trial included patients with a range of RAS variants and those without an identified tumor RAS mutation.
Revolution Medicines said the trial met its primary and key secondary goals. These included measures of survival and how long patients lived without their cancer progressing.
In trials involving patients with pancreatic adenocarcinoma, skin toxicity occurred in 86% of those treated with RASONQUE, the company said. Diarrhea occurred in 63%, while 57% experienced mouth inflammation.
Serious adverse reactions occurred in 30% of patients treated with the drug. The company also warned of gastrointestinal perforation and lung inflammation; one event in each category was fatal.
RASONQUE is already approved in the United States for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy. The US approval also covers patients who are not candidates for systemic treatment with multiple drugs.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI

- 3NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur

- 4Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds

- 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings

Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists















